Moreover, patients treated in the SEQUOIA-HCM trial with aficamten, a myosin inhibitor with a more shallow dose–response relationship with respect to mavacamten, presented more hypertension with respect to placebo (7.7% vs. 2.1%),8 potentially suggesting a class effect. This evidence concerns the gene MYH14 and hypertensive disorder.